AR107548A1 - Forma cristalina a de agonista de tlr7, su proceso de preparación y uso - Google Patents

Forma cristalina a de agonista de tlr7, su proceso de preparación y uso

Info

Publication number
AR107548A1
AR107548A1 ARP170100297A ARP170100297A AR107548A1 AR 107548 A1 AR107548 A1 AR 107548A1 AR P170100297 A ARP170100297 A AR P170100297A AR P170100297 A ARP170100297 A AR P170100297A AR 107548 A1 AR107548 A1 AR 107548A1
Authority
AR
Argentina
Prior art keywords
preparation
tlr7 agonist
glrist
use process
crystalline form
Prior art date
Application number
ARP170100297A
Other languages
English (en)
Spanish (es)
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of AR107548A1 publication Critical patent/AR107548A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP170100297A 2016-02-05 2017-02-06 Forma cristalina a de agonista de tlr7, su proceso de preparación y uso AR107548A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610082029.8A CN107043379A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的晶型a、其制备方法和医药用途

Publications (1)

Publication Number Publication Date
AR107548A1 true AR107548A1 (es) 2018-05-09

Family

ID=59499348

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100297A AR107548A1 (es) 2016-02-05 2017-02-06 Forma cristalina a de agonista de tlr7, su proceso de preparación y uso

Country Status (27)

Country Link
US (2) US10442811B2 (enrdf_load_stackoverflow)
EP (1) EP3412672B1 (enrdf_load_stackoverflow)
JP (1) JP6889171B2 (enrdf_load_stackoverflow)
KR (1) KR102393280B1 (enrdf_load_stackoverflow)
CN (2) CN107043379A (enrdf_load_stackoverflow)
AR (1) AR107548A1 (enrdf_load_stackoverflow)
AU (1) AU2017215801B2 (enrdf_load_stackoverflow)
CA (1) CA3013518C (enrdf_load_stackoverflow)
CL (1) CL2018002092A1 (enrdf_load_stackoverflow)
DK (1) DK3412672T3 (enrdf_load_stackoverflow)
EA (1) EA035951B1 (enrdf_load_stackoverflow)
ES (1) ES2830443T3 (enrdf_load_stackoverflow)
HR (1) HRP20201644T1 (enrdf_load_stackoverflow)
HU (1) HUE051399T2 (enrdf_load_stackoverflow)
IL (1) IL260968B (enrdf_load_stackoverflow)
LT (1) LT3412672T (enrdf_load_stackoverflow)
MX (1) MX374297B (enrdf_load_stackoverflow)
NZ (1) NZ744884A (enrdf_load_stackoverflow)
PH (1) PH12018501643A1 (enrdf_load_stackoverflow)
PL (1) PL3412672T3 (enrdf_load_stackoverflow)
PT (1) PT3412672T (enrdf_load_stackoverflow)
SG (1) SG11201806683UA (enrdf_load_stackoverflow)
SI (1) SI3412672T1 (enrdf_load_stackoverflow)
TW (1) TWI754629B (enrdf_load_stackoverflow)
UA (1) UA121161C2 (enrdf_load_stackoverflow)
WO (1) WO2017133684A1 (enrdf_load_stackoverflow)
ZA (1) ZA201805186B (enrdf_load_stackoverflow)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
KR20210013183A (ko) * 2018-05-25 2021-02-03 치아타이 티안큉 파마수티컬 그룹 주식회사 Tlr7 작용제 및 폐암을 치료하기 위한 이의 약학 조합물
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
EP3937944A1 (en) * 2019-03-15 2022-01-19 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Toll-like receptor agonists for use in the treatment of hepatitis b
PH12021552643A1 (en) * 2019-04-23 2022-07-11 Chia Tai Tianqing Pharmaceutical Group Co Ltd Solid pharmaceutical composition comprising tlr7 agonist
AU2021231160A1 (en) 2020-03-02 2022-09-22 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
EP4194010A4 (en) 2020-08-04 2025-03-26 Progeneer Inc. Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
WO2007024707A2 (en) * 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
US9139590B2 (en) * 2011-02-04 2015-09-22 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) * 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
NZ705589A (en) * 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
RU2643371C2 (ru) 2012-11-20 2018-02-01 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
RU2640200C2 (ru) 2012-11-20 2017-12-27 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
BR112015011400A8 (pt) * 2012-11-20 2019-10-01 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
EA030603B1 (ru) * 2014-05-01 2018-08-31 Новартис Аг СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ АГОНИСТОВ Toll-ПОДОБНОГО РЕЦЕПТОРА 7
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
CN105367576A (zh) 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途

Also Published As

Publication number Publication date
AU2017215801B2 (en) 2020-09-10
PH12018501643A1 (en) 2019-06-03
CA3013518A1 (en) 2017-08-10
US20190040071A1 (en) 2019-02-07
EP3412672B1 (en) 2020-07-15
HK1259170A1 (zh) 2019-11-29
EA035951B1 (ru) 2020-09-04
CN108602831B (zh) 2020-11-03
LT3412672T (lt) 2020-11-10
WO2017133684A1 (zh) 2017-08-10
EP3412672A1 (en) 2018-12-12
MX374297B (es) 2025-03-06
PL3412672T3 (pl) 2021-01-25
CN108602831A (zh) 2018-09-28
SG11201806683UA (en) 2018-09-27
PT3412672T (pt) 2020-11-11
EP3412672A4 (en) 2019-07-17
US20200039988A1 (en) 2020-02-06
HUE051399T2 (hu) 2021-03-01
EA201891768A1 (ru) 2019-01-31
MX2018009501A (es) 2018-12-11
TW201728589A (zh) 2017-08-16
CN108602831B9 (zh) 2020-12-04
KR102393280B1 (ko) 2022-05-02
UA121161C2 (uk) 2020-04-10
JP6889171B2 (ja) 2021-06-18
CL2018002092A1 (es) 2018-12-07
NZ744884A (en) 2022-09-30
US10442811B2 (en) 2019-10-15
CN107043379A (zh) 2017-08-15
JP2019505533A (ja) 2019-02-28
HRP20201644T1 (hr) 2020-12-25
SI3412672T1 (sl) 2021-02-26
AU2017215801A1 (en) 2018-08-23
KR20180104117A (ko) 2018-09-19
ES2830443T3 (es) 2021-06-03
DK3412672T3 (da) 2020-10-19
CA3013518C (en) 2022-07-19
US10947245B2 (en) 2021-03-16
ZA201805186B (en) 2024-08-28
BR112018015880A2 (pt) 2018-12-26
IL260968B (en) 2022-05-01
TWI754629B (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
AR107548A1 (es) Forma cristalina a de agonista de tlr7, su proceso de preparación y uso
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
MX375353B (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
AR101403A1 (es) (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carboxamida, su purificación para su uso como principio activo farmacéutico, un procedimiento para su preparación y su empleo en el tratamiento de enfermedades cardiovasculares
AR107550A1 (es) Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización
DOP2014000203A (es) Compuestos de heterociclilo
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
AR096046A1 (es) Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
AR096758A1 (es) Inhibidores cristalinos de bromodominios
PH12016500250B1 (en) Novel triazolo [4,5-d] pyrimidine derivatives
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
BR112015031619A2 (pt) forma cristalina estável de cloridrato de tipiracil e método de cristalização para a mesma
PT3541814T (pt) Compostos de amino-naft[1,2-d]imidazol-5-ona 2-substituída ou seus sais farmaceuticamente aceitáveis
MX2015014081A (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor de canabinoides 2 (cb2).
MX382724B (es) Formas sólidas de ceftolozano.
AR099082A1 (es) Formas sólidas de tenofovir
AR098747A1 (es) Formas polimórficas de un compuesto similar a esteroides y métodos para su preparación y uso
CO2017002070A2 (es) Un proceso para la preparación de derivados de 3-fenil/heteroaril-6-fenoxi-8-alquilamino-imidazo[1,2-b] piridazina
IN2013CH03945A (enrdf_load_stackoverflow)

Legal Events

Date Code Title Description
FC Refusal